AHC interview with Heinz Reischer.

May 2, 20180:00:20-0:07:48 Overview of life in Vienna and Brussels0:07:51-0:10:46, 1:13:18-1:14:29, 0:19:53-0:22:42 Religious life0:10:50-0:16:10 Memories of his parents and his brother0:16:15-0:19:47 Canadian war orphans project0:23:44-0:32:56 Deportation of parents0:33:00-0:36:08 Wearing a yellow badge in Brussels0:37:12-0:41:04, 1:24:49-1:28:33 Orphanages in Brussels0:48:53-1:05:10 Route from Brussels to Montreal1:05:14-1:09:18 Life in Montreal1:11:20-1:13:17 Recollections of his neighborhood in Vienna1:14:40-1:16:54 Recollections of “Anschluss” and “Kristallnacht”1:28:38-1:31:35 Memories of the end of the war1:31:36-1:33:53 Anti-Semitism1:33:58-1:39:22 Thoughts on Israel1:41:20-1:46:55 Austria’s dealing with its NS-past1:53:08-1:54:19 Final messageHeinz Reischer was born on August 19, 1930 in Vienna, Austria. He grew up with his older brother Erich and their parents Milan Reischer and Margarete née Ehrenreich in an apartment in Franz-Hochedlinger-Gasse 26, in Vienna’s second district. Heinz attended school in Vienna until he escaped to Brussels in 1938. There he went to school and lived with his family until 1942, when his parents got deported. From then on Heinz lived in orphanage. At the end of 1947 the Canadian Jewish Congress sponsored a rescue mission for orphans, and Heinz emigrated to Canada: he boarded the “Aquitania” in Southampton, England to Toronto, Ontario. Heinz moved to Montreal and started working in sales.Austrian Heritage Collectio

Dalbavancin for treatment of implant-related methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model

Dalbavancin is a new semisynthetic lipoglycopeptide with improved antimicrobial activity against various gram-positive pathogens. It demonstrates an extensive plasma half-life which permits outpatient parenteral antimicrobial therapy with weekly intervals and might therefore be an excellent treatment alternative for patients requiring prolonged antimicrobial therapy. The present study investigated dalbavancin monotherapy in an experimental implant-related methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis model. A clinical MRSA isolate and a Kirschner-wire were inserted into the proximal tibia of anaesthetized Sprague-Dawley rats. Four weeks after infection 34 animals were treated over 4 weeks with either dalbavancin (20mg/kg loading-dose; 10mg/kg daily), vancomycin (50mg/kg twice daily) or left untreated. Twenty-four hours after the last treatment dose tibial bones and Kirschner-wires were harvested for microbiological examination. Based on quantitative bacterial cultures of osseous tissue, dalbavancin was as effective as vancomycin and both were superior to no treatment. No emergence of an induced glycopeptide-/lipoglycopeptide- resistance was observed after a treatment period of four weeks with either dalbavancin or vancomycin. In conclusion, monotherapy with dalbavancin was shown to be as effective as vancomycin for treatment of experimental implant-related MRSA osteomyelitis in rats, but both antimicrobials demonstrated only limited efficacy. Further studies are warranted to evaluate the clinical efficacy of dalbavancin for the treatment of periprosthetic S. aureus infections.(VLID)464184